Ruti Aga's Six-Year Ban: One Forged Prescription, Three Lies, and the Medical Vacuum Behind Elite Marathon
**मुख्य उत्तर:** रुति आगा को एथलेटिक्स इंटीग्रिटी यूनिट ने छह साल का प्रतिबंध दिया: मार्च में चीन की हाफ मैराथन जीतने के बाद मिथाइलप्रेडनिसोलोन (WADA श्रेणी S9 ग्लूकोकॉर्टिकोइड) के लिए पॉज़िटिव टेस्ट पर दो साल, और नकली पर्चा पेश करने पर चार साल। प्रतिबंध 10 सितंबर से प्रभावी है। **मुख्य तथ्य:** - दो साल उपस्थिति अपराध पर, चार साल छेड़छाड़ पर — कुल छह साल का प्रतिबंध, 10 सितंबर से। - मिथाइलप्रेडनिसोलोन एनाबॉलिक स्टेरॉयड नहीं, ग्लूकोकॉर्टिकोइड (S9) है; केवल प्रतियोगिता के दौरान प्रतिबंधित। - पर्चा एक ऐसे क्लिनिक के नाम पर था जिसका अस्तित्व ही नहीं; लिखने वाला परिवार का अपंजीकृत सदस्य था। - आगा 2019 टोक्यो मैराथन विजेता हैं और तीन वर्ल्ड मैराथन मेजर में दूसरा स्थान रखती हैं। - 32 वर्ष की आयु में छह साल का प्रतिबंध वापसी को लगभग 38 की उम्र तक धकेल देता है। **स्रोत:** एथलेटिक्स इंटीग्रिटी यूनिट (AIU) का आधिकारिक बयान, जिसमें उपस्थिति और छेड़छाड़ के दोनों निष्कर्ष दर्ज हैं; प्रतिबंध की प्रभावी तिथि 10 सितंबर। **संबंधित प्रश्न-उत्तर:** प्रश्न: क्या ग्लूकोकॉर्टिकोइड इंजेक्शन पूरी तरह प्रतिबंधित है? उत्तर: नहीं — WADA सूची की श्रेणी S9 के तहत यह केवल प्रतियोगिता के दौरान और केवल इंजेक्शन, मुँह या रेक्टल रास्ते से प्रतिबंधित है; प्रतियोगिता से बाहर चिकित्सीय उपयोग वैध है। प्रश्न: छह साल की सज़ा किन दो हिस्सों से बनी? उत्तर: दो साल प्रतिबंधित पदार्थ की उपस्थिति पर और चार साल नकली प्रिस्क्रिप्शन पेश करने तथा भ्रामक बयान देने पर। प्रश्न: क्या उनका 2019 टोक्यो खिताब रद्द होगा? उत्तर: नहीं, क्योंकि उल्लंघन बाद की किसी प्रतियोगिता से जुड़ा है और पहले के उपयोग का कोई निष्कर्ष दर्ज नहीं है; रद्दीकरण का दायरा मार्च वाली रेस तक सीमित रहने की प्रबल संभावना है।
The clinic's name appears in no registry. The person who signed the prescription holds no medical licence — he was a family member. And the paper the whole structure stood on was a blank pad lifted from a former workplace. When the Athletics Integrity Unit checked the claim, the institution printed on that pad disowned it in plain words: this is not ours, and it never was.
Three separate checks. Three separate denials. One piece of paper.
That paper fixed six years of Ruti Aga's career.
I have met paper-and-syringe stories before. In April 2026 I was in the host chair in Gold Coast when Neeraj Chopra won javelin gold, and within days a syringe turned up in the Indian team's village accommodation and my broadcast became a corridor of denials, paperwork and half-answers. That taught me the thing that matters most here: in doping cases the sentence is usually decided not by the substance but by the paperwork written afterwards. A syringe in Gold Coast taught me that recovery is a public performance. Here, years later, the same lesson is being taught again, in the name of an Ethiopian marathoner.
One technical correction before anything else, because the words matter more than the sanction in this story. Methylprednisolone has been reported worldwide as a "prohibited steroid." That is imprecise. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9 — not an anabolic steroid (S1). And S9 carries a specific condition: it is prohibited in-competition only, and only by injection, oral or rectal route. A therapeutic knee injection, given out of competition, is entirely legal.

That distinction is not pharmacology trivia. It is the legal hinge of the entire case.
The name that never reached a podium
Aga belongs to the Ethiopian generation that turned women's marathon into a national production system. The numbers in my notebook beside her name — second in Berlin 2026, around 2:18:34; first in Tokyo 2026, around 2:20:40 — come from my own record and await official cross-checking, so read them with care. What needs no verification: three second-place finishes at World Marathon Majors, and the 2026 Tokyo Marathon title.

It is a strange record. Magnificent and unfinished. Three Major second places put you just below the very best and nowhere near the rest. I keep a particular ledger — an accounting of the just-off-podium: Milkha Singh's fourth at Rome 2026, P. T. Usha beaten by a hundredth at Los Angeles 2026, the men's 4x400 fifth in Budapest with an Asian record set in the heats. That ledger is inheritance, not failure. Aga's three runner-up finishes belong in it too — except that her page has now been sealed by a disciplinary decision.
And it matters what 2:18 means in Ethiopia. The depth is such that world-record-class runners sit out domestic selection. A 2:18 performer is not automatically selectable. Which is why Aga's career was built where the money is, not where the championships are — the Majors, and between them the label races of Asia.
The Chinese half marathon: where appearance fees and testing collide
In March, Aga won a half marathon in China. The mark appears nowhere in the reporting — no split, no field strength. So any performance claim would be invention, and I do not put guesses where numbers go. The only usable information is that she won, and that the race carried an AIU in-competition test, which means a World Athletics Label-tier elite women's field.
For East African marathoners this circuit is a clean economic tier: appearance fee, low risk, low mileage, between Majors. No agent leaves that gap empty. And it is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races.
One technical point carries the case. A road race's in-competition testing window opens at 23:59 the day before the race. Which means a glucocorticoid injected into a knee four or five days earlier — standard sports medicine for runner's knee synovitis — can be caught in-competition even though the injection itself was lawful.
The patch notes arrived before the players did. When the List moved glucocorticoids into in-competition prohibition by injection, oral and rectal route, anyone running on old rules had two options: a TUE, or the washout period. Neither appears to have happened.
Two years, then four: read the arithmetic as arithmetic
The AIU decision sounds like a narrative. It is a sum. Two years for presence — the prohibited substance in the sample. Four years for tampering — the forged prescription and misleading statements under questioning. Six in total.
The sum is itself information. The two-year figure tells us the panel rejected the no-significant-fault mitigation. With genuine medical records and a documented knee history, the presence charge could have been argued at the no-fault end — potentially a reprimand — and no tampering charge would exist at all. The four-year figure is the Code's standard tampering sanction; there is no exceptional harshness in it.
The near-paradox: forged documentation is circumstantial evidence of concealment intent, yet it did not escalate the presence sanction. Legally correct. Humanly odd. One sheet of paper wearing two different crimes.
The ban runs from 10 September, backdated to provisional suspension. That is often mistaken for leniency. Backdating is a procedural benefit, not a reduction — the time already served outside is simply counted inside. The ledger balances.
The four years that came from an interview, not a drug
This is the least examined part. The tampering sanction did not come from a document alone. It came from an interview — from statements made under questioning. That is why it is so hard to overturn. Language and translation conditions in AIU interviews with East African athletes are a recurring point of contention. I am not alleging misconduct here; I am saying that when an athlete gives evidence outside her first language inside a process where every sentence may become legal, she needs counsel and a trained representative in the room. That is a system question, and it is bigger than the drug.
Now back to the knee. A knee injury was cited as the reason for treatment. That explanation is entirely plausible — chronic knee synovitis is routine in high-volume marathoners and intra-articular methylprednisolone is standard care. And that plausibility is the cruellest fact in the file: if the treatment was real, real records would have defended it. The forged prescription is the strongest available evidence that real records did not exist.
Three independent failures: the name was false, the person was unregistered, the pad was disowned. This is not a filing error. It is the signature of an athlete operating without a credentialed team physician.
The empty TUE chair
A properly managed athlete has two routes: a TUE, or route-and-timing-compliant washout. Neither appears. My inference, and I flag it as inference: the decision to forge suggests the lawful route was either closed or unknown. Either way the fault lands in the same place — a team, a management structure, a medical support layer that was simply not there.
The knee is the causal entry point of this case, and it is a systemic signal rather than an individual one. An injured marathoner has a strong incentive to mask pain: the appearance fee is the income, and skipping a race weakens next season's bargaining. Glucocorticoids are the cheapest available tool for that. The surrounding network is informal. The forgery is the last link in the chain, not the first.
The part the reporting broke
Here I reach for an old habit, learned in Bhubaneswar in 2026 when I wrote every athlete introduction as a champion select and refused to read a bio aloud until I found the stat that bends the story — three lines of patch note: what changed, why it matters, who exploits it. In this story the first line was printed wrong.
"Prohibited steroid" sends the reader toward a different and wrong story: muscle, hidden gain, deceit. What was actually there was an anti-inflammatory with no proven endurance benefit, legal out of competition. The press made the charge heavier than it legally was, and in doing so buried the only lesson worth taking. The athlete had a legitimate defence available — timing, route, medical necessity. She destroyed it herself with a forged prescription.
The contrarian read: is six years disproportionate?
My answer comes in two halves, and they must be held together. First: the severity did not come from the drug. It came from the paper. With real records there is no case and no article. The six-year figure is the price of choosing paper over truth, not the price of a glucocorticoid.
Second, and more important: what is genuinely disproportionate is not the sentence but the medical vacuum. A 32-year-old elite, a Major winner, three Major runner-up finishes, had no registered physician for her treatment. She had a relative and an old pad. This is not a story of wealthy institutions against a poor runner, however easily it sells that way. It is a story about an athlete whose career moves real money while her clinical support runs on a phone call — a failure nobody prevents, nobody records, and nobody is sanctioned for.
One case, or a category?
Across recent years a pattern is visible: East African road-running cases where an initial substance violation is compounded by a fabricated or altered explanation. The enforcement frontier has shifted from detection to document verification. The AIU is litigating paperwork more often than pharmacology.
That has a concrete consequence nobody discusses. Athletes built inside one training cluster, under one agent, on one informal medical network, can fall inside the same investigation when one case surfaces. I expect similarly profiled cases in the pipeline, because the network that produced this prescription did not serve one runner. And note what is absent from the record: any statement from the Ethiopian federation. Only the AIU speaks. That silence is information.
What survives
The March result and its prize money will almost certainly be annulled, standard AIU practice for the competition where the sample was collected, along with ranking points from that date. The 2026 Tokyo title predates it, and absent a finding of earlier use, earlier results are not automatically void. That is a fine line, and it decides what history keeps: one Major title no piece of paper took away, and three second places that never reached a podium.

At 32, with a six-year ban, the return age is roughly 38. In Ethiopian women's marathon depth, a 38-year-old with a doping record is effectively unselectable. On paper the ban is six years; in career terms it is lifetime. And the causal factor was neither the drug nor the paper. It was the knee.
A CAS window — typically around 21 days from the reasoned decision — will open. My read is that its value is low: a document-based forgery finding is hard to overturn when three independent verifications have already failed. Criminal exposure for document forgery sits outside AIU jurisdiction, and no referral has been mentioned.
The real question is not what happens next. It is what happens the next time a marathoner's knee swells, and there is no TUE, and no doctor on the team. Will she have a route that does not require an old prescription pad? Until that answer exists, this stays filed as one person's mistake. It is a system's mistake. A host is just a translator between the scoreboard and the story. The scoreboard here is empty. The story is still owed.
